Author

Nicholas Omniewski

Observed name: Nicholas D Omniewski

Institution: Ironwood Pharmaceuticals (United States)

Observed institution: Ironwood Pharmaceuticals (United States)

OpenAlex ID: A5037965097

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

2017 · Philip Schoenfeld, Brian E Lacy, et al. · The American Journal of Gastroenterology · 75

Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System

2021 · Lin Chang, Brian E. Lacy, et al. · The American Journal of Gastroenterology · 56

Targeted Delivery of Linaclotide to Specific Areas of The Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

2017 · William D. Chey, Paul Chamberlin, et al. · Gastroenterology · 6

Mo1550 A NOVEL SCORE TO EVALUATE ABDOMINAL SYMPTOM IMPROVEMENT IN PATIENTS WITH CONSTIPATION-PREDOMINANT IBS DEMONSTRATES EFFICACY OF LINACLOTIDE FOR IMPROVING ABDOMINAL BLOATING, DISCOMFORT, AND PAIN IN A PHASE 3B TRIAL

2020 · Lin Chang, Brian E. Lacy, et al. · Gastroenterology · 3

Works count: 4

Citation count: 140

H-index: 3

I10-index: 2